# Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

> **NCT03112590** · PHASE1,PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 51 (actual)

## Conditions studied

- Breast Cancer
- Breast Cancer, Male
- Breast Cancer Female
- HER2-positive Breast Cancer

## Interventions

- **BIOLOGICAL:** Interferon-gamma (IFN-γ)
- **DRUG:** Paclitaxel
- **DRUG:** Trastuzumab
- **OTHER:** Pertuzumab
- **PROCEDURE:** Post Therapy Surgery

## Key facts

- **NCT ID:** NCT03112590
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-23
- **Primary completion:** 2021-03-31
- **Final completion:** 2023-02-20
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2023-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03112590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03112590, "Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03112590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*